Lead Sponsor

BeiGene

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Participants have voluntarily agreed to participate by giving written informed consent.
•2. Age 18 years (including 18 years) on the day of signing informed consent.
•3. Participants meet the following eligibility criteria for the corresponding part of the study: 1) In Phase 1 portion: The participants must have a histologically or cytologically confirmed locally advanced or metastatic cancer, either triple-negative breast cancer or epithelial, non-mucinous, high-grade ovarian cancer (including fallopian cancer, or primary peritoneal cancer), for which no effective standard therapy is available.
•2\) In Phase 2 portion: Participants who have histologically or cytologically confirmed high-grade epithelial ovarian cancer (including fallopian cancer or primary peritoneal cancer), harboring germline BRCA1/2 mutation 4. Participants must have measurable disease as defined per the RECIST, version 1.1.
•5\. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

•1. Participants who have been treated with chemotherapy, biologic therapy, immunotherapy, investigational agent, anti-cancer Chinese medicine, or anticancer herbal remedies ≤ 14 days (or ≤5 half-lives, whichever is shorter) prior to starting study drug, or who have not adequately recovered from the side effects of such therapy.
•2. Participants who have undergone major surgery for any cause ≤ 4 weeks prior to starting study drug. Participants must have adequately recovered from the previous treatment and have a stable clinical condition before entering the study.
•3. Participants who have undergone radiotherapy for any cause ≤ 14 days prior to starting study drug. Participants must have adequately recovered from the previous treatment and have a stable clinical condition before entering the study.
•4. Untreated and/or active brain metastases.
•5. Prior therapies targeting poly (ADP-ribose) polymerase (PARP).

Related studies

NCT07069595 · Breast Cancer, Residual Disease, and more

NCT06681064 · Breast Cancer, Triple Negative Breast Cancer, and more

NCT05005403 · Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more

NCT06547840 · Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, and more

NCT06451497 · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors